Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model.
In a syngeneic murine model of multiple myeloma with many of the characteristics of the human disease, a monoclonal antibody (mAb) to the integrin very late antigen-4 (VLA-4), given after the myeloma has already homed to and begun to establish itself within the bone marrow compartment, produces statistically significant effects on multiple disease variables. These include reductions in circulating levels of IgG2b; percentage of IgG2b-positive myeloma cells circulating in blood; spleen weight; and myeloma cell burden in spleen, bone marrow, and liver. mAb therapy had no effect on nonmalignant hematopoietic cells. An acute 6-day regimen of mAb treatment, initiated very late in disease to avoid mAb elimination in the immunocompetent animals, still significantly reduced spleen and blood myeloma cell burden. The ability of the (VLA-4) mAb to affect multiple variables in this model, even as monotherapy, suggests this pathway plays a central role in disease progression.
Olson
Dian L
DL
Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA. Dian.Olson@BiogenIdec.com
Burkly
Linda C
LC
Leone
Diane R
DR
Dolinski
Brian M
BM
Lobb
Roy R
RR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D039441:Integrin alpha4 / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*
D000911:Antibodies, Monoclonal; D039441:Integrin alpha4